Antimony Trisulfide Iris Germanica Root Pulsatilla
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Antimony Trisulfide Iris Germanica Root Pulsatilla
- Multi-component Homeopathic Mixture: Unable to Generate Drug Repurposing Prediction Report
Multi-component Homeopathic Mixture: Unable to Generate Drug Repurposing Prediction Report
One-Sentence Summary
This product is a multi-component homeopathic/herbal mixture (containing Antimony Trisulfide, Iris Germanica Root, Pulsatilla Vulgaris, Silver Nitrate, Sulfur, Thuja Occidentalis Leafy Twig, Tribasic Calcium), currently with no approval records in the United States and no corresponding DrugBank ID. The TxGNN model generated no drug repurposing predictions, likely because this multi-component mixture cannot find corresponding nodes in the knowledge graph. Therefore, this report is an insufficient data notification, not a complete drug repurposing assessment report.
Quick Overview
| Item | Content |
|---|---|
| Original indication | No data |
| Predicted new indications | None (TxGNN generated no predictions) |
| TxGNN prediction score | None |
| Evidence level | L5 (model unable to assess) |
| US market status | Not marketed |
| NDA count | 0 |
| Recommended decision | Hold |
Why were no predictions generated?
This product is a homeopathic complex containing seven components with the following characteristics that prevent the TxGNN workflow from functioning normally:
1. No DrugBank ID The TxGNN knowledge graph uses DrugBank ID as the node identifier. Although querying DrugBank for this product returned 1 result, a valid DrugBank ID could not be obtained, indicating unclear correspondence. A drug node cannot be established in the knowledge graph.
2. Mapping challenges for multi-component mixtures Homeopathic complexes (such as this product) are typically registered as a whole mixture of components rather than as a single active ingredient. TxGNN is designed for prediction on single chemical entities; complex mixtures lack unified nodes in the KG, preventing the prediction workflow from initiating.
3. No approval records in the United States FDA query results are zero, indicating this complex may be registered as an OTC homeopathic product (not requiring NDA), or is not marketed in the United States at all. The regulatory pathway for homeopathic products differs from that of conventional drugs, resulting in missing indication data.
US Market Information
Currently no NDA or market records.
This product has no approval or market records in the United States (total_licenses = 0). Homeopathic products in the United States are typically filed through different regulatory pathways. It is recommended to query the FDA homeopathic products database or OTC Monograph system to confirm market status.
Safety Information
Currently no available safety data. Please refer to the individual product labeling and relevant literature for each component.
Note: This complex contains Silver Nitrate and Antimony Trisulfide, both inorganic compounds with potential toxicity. In the absence of complete safety data, careful evaluation of use-related risks is warranted.
Conclusion and Next Steps
Decision: Hold (suspend evaluation)
Rationale: This product is a multi-component homeopathic complex. The TxGNN model failed to identify corresponding drug nodes in the knowledge graph, therefore unable to generate drug repurposing predictions. Without foundational data, meaningful drug repurposing assessment cannot be performed.
If continued evaluation is needed, the following data must be supplemented:
- Clarify active components: Confirm the DrugBank ID for each component in the complex, consider executing TxGNN predictions for each component separately, then consolidate the results.
- Confirm regulatory pathway: Query the FDA homeopathic OTC database to clarify whether it is registered as an OTC product, and obtain approved indication data.
- Obtain safety data: Download and analyze FDA or EMA Monographs for relevant individual components, and supplement warnings and contraindication information.
- Re-execute mapping workflow: Re-perform DrugBank mapping and TxGNN prediction on an individual component basis (such as Sulfur, Silver Nitrate, etc.).
- Assess feasibility of split reports: If individual components have sufficient KG coverage, consider generating separate drug repurposing assessment reports for each major component.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.